3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
9
Thoracic
3
Gastrointestinal
3
Other solid neoplasm
2
Gynecologic
2
Sarcoma
1
NET
1
Genitourinary
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
43
Melanoma
19
Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
11
Neoplasm Metastasis
11
Carcinoma, Non-Small-Cell Lung
9
Breast Neoplasms
9
Glioblastoma
8
Colorectal Neoplasms
8
Triple Negative Breast Neoplasms
7
Pancreatic Neoplasms
7
Ovarian Neoplasms
7
Gliosarcoma
7
Lung Neoplasms
6
Histiocytoma, Malignant Fibrous
6
Carcinoma, Renal Cell
6
Osteosarcoma
5
Liposarcoma
5
Head and Neck Neoplasms
5
Carcinoma, Hepatocellular
5
Uterine Cervical Neoplasms
4
Sarcoma, Synovial
4
Sarcoma, Kaposi
4
Neurofibrosarcoma
4
Lymphoma
4
Hemangiosarcoma
4
Carcinoma, Merkel Cell
4
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Recurrence
3
Interventions
Docetaxel
3
trastuzumab deruxtecan
2
entrectinib
2
Magnetic Resonance Spectroscopy
2
Fluorodeoxyglucose F18
2
Erlotinib Hydrochloride
2
Biopsy
2
pembrolizumab
1
larotrectinib
1
entinostat
1
ceralasertib
1
alectinib
1
Thalidomide
1
Taxes
1
Specimen Handling
1
Ritonavir
1
Radiotherapy
1
Quality of Life
1
Polymerase Chain Reaction
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Irinotecan
1
Indinavir
1
Immunotherapy
1
Immunohistochemistry
1
Gene Expression Profiling
1
Gemcitabine
1
Fluorescent Antibody Technique
1
Flow Cytometry
1
Filgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
pembrolizumab
×
Sarcoma
×
Clear all
NCT04140526
2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2
Active not recruiting
733 enrolled